NCT06327880

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-07054894 IN HEALTHY ADULT JAPANESE PARTICIPANTS

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (PF-07054894) in healthy Japanese participants. The study is seeking the following participants: * Male or female Japanese participants aged 18 years or older. The participants should be healthy after going through some medical tests. * Have a Body Mass Index (BMI) of 16 to 32 kilogram per meter squared; and a total body weight of more than 45 kilograms (100 pounds). * Are willing and able to follow all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. In research, the participants in clinical studies are assigned by chance to separate groups that are given different treatments. Hence participants will be by chance assigned to receive either PF-07054894 or a harmless treatment that has no medical effect (placebo). Both these will be taken by mouth for 14 days. The total duration of the study is about 11 weeks, with a follow-up via telephone about 6 weeks after first treatment.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-07054894 or placebo	multiple oral doses of PF-07054894 for 14 days

Timeline

• Start date: 2024-05-13
• Primary completion: 2024-07-02
• Completion: 2024-07-02
• First posted: 2024-03-25
• Last updated: 2024-08-05

Locations

1 site across 1 country: Belgium

Regulatory

• FDA-regulated drug study